Efficacy of certain immunotherapeutic strategies, such as inhibition of immune checkpoints i.e. PD-L1 blockade, often depend on the concentration of tumour infiltrating lymphocytes (TILs) and CD8+-T-cells in the tumour microenvironment. Here, CD8A is linked to neoplasm.